Philipp E. Zurkinden

A stable and comprehensible legal framework is of great importance, not only in crisis situations, but in general. Legal uncertainties are poison for the supply of a country with important medical goods. The life sciences sector has so far not raised any major competition law issues in Switzerland. Yet, recent jurisprudence as well as enacted and planned legislative amendments are not free of contradictions and ambiguities. The lack of an update of the Mutual Recognition Agreement and the related status of Switzerland as a third country vis-à-vis the EU brought additional uncertainties. The authors provide an overview of the current regulatory environment and discuss the implications of planned legislative changes.

This annual report on jurisprudence in Swiss competition law in 2019/20 summarizes the most important cartels, abuse of dominance and merger cases in this period. It further contains some comments on three state aid cases falling under the bilateral air transport agreement CH-EU in 2020 and on the ongoing reform of the Swiss Cartels Act.

This article provides an overview on the recent practice of the Swiss competition authorities in merger control and on the ongoing reform of the Swiss Cartels Act and the merger control reform respectively